type-2-diabetes

Documents about type-2-diabetes

• A Drug Interaction Study With Albiglutide and Warfarin#121264ClinicalTrials.gov
• Effect on Weight Loss of Exenatide Versus Placebo#146394ClinicalTrials.gov
• Study of Sulphonylurea Synergy With DPP4 Inhibitors#146417ClinicalTrials.gov
• Glycemic Durability After Metformin Failure#146430ClinicalTrials.gov
• Fit 24 Technology Intervention YOUTH#152582ClinicalTrials.gov
• Forxiga Tablets Specific Clinical Experience Investigation for Elderly#152596ClinicalTrials.gov
• An Extension Study of PEAK Trial#154882ClinicalTrials.gov
• Pharmacokinetics of Metformin Intolerance#181738ClinicalTrials.gov
• Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone#28582ClinicalTrials.gov
• ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia#146391ClinicalTrials.gov
• Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes#158174ClinicalTrials.gov
• Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin#136289ClinicalTrials.gov
• A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before#140961ClinicalTrials.gov
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease#143713ClinicalTrials.gov
• Transition to Hospital Discharge in Insulinized Patients With Type 2 Diabetes Mellitus#148722ClinicalTrials.gov
• The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.#162361ClinicalTrials.gov
• Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes#195512ClinicalTrials.gov
• Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus#195521ClinicalTrials.gov
• Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes#146407ClinicalTrials.gov
• Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study#5153Europe PMC
• A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients#67837ClinicalTrials.gov
• Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial#143762ClinicalTrials.gov
• A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy#146372ClinicalTrials.gov
• Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs#158173ClinicalTrials.gov
• A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes#162427ClinicalTrials.gov
• Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus#180347ClinicalTrials.gov
• Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"#181722ClinicalTrials.gov
• Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy#28546ClinicalTrials.gov
• A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas#121269ClinicalTrials.gov
• Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin#127805ClinicalTrials.gov
• Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.#127806ClinicalTrials.gov
• Estimation of Glomerular Filtration Rate (GFR) in Patients With Type 2 Diabetes Mellitus.#136240ClinicalTrials.gov
• Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes#136277ClinicalTrials.gov
• Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.#162426ClinicalTrials.gov
• Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy#181714ClinicalTrials.gov
• A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects#148702ClinicalTrials.gov
• Reducing Plasma Glucose Effect of Cinnamon in Type 2 Diabetic Patients in the Municipality of Comasagua#154867ClinicalTrials.gov
• A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients#126045ClinicalTrials.gov
• Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment#154808ClinicalTrials.gov
• Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)#28529ClinicalTrials.gov
• iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)#28569ClinicalTrials.gov
• The OBSTACLE Hypoglycemia Study (MK-0000-158)#67777ClinicalTrials.gov
• Glucose Reduction by Early Acarbose Treatment in Basal Insulin#123403ClinicalTrials.gov
• GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin#126053ClinicalTrials.gov
• Acetylcarnitine and Insulin Sensitivity#143712ClinicalTrials.gov
• Reandron in Diabetic Men Witn Low Testosterone Level#143746ClinicalTrials.gov
• The Fructose and Allulose Catalytic Effects (FACE) Trial#146366ClinicalTrials.gov
• Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination#152351ClinicalTrials.gov
• LIraglutide and Beta-cell RepAir (LIBRA) Study#158134ClinicalTrials.gov
• Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients#160270ClinicalTrials.gov